Published: March 22, 2026 · Last updated: April 28, 2026
- GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce 12–18% placebo-corrected weight loss in clinical trials — but stopping the medication usually leads to regain unless lifestyle changes carry the result forward (NIH PMC).
- The FDA has issued safety communications about acute pancreatitis, gallbladder disease, severe gastrointestinal effects, and concerns about unapproved compounded versions of these drugs.
- Mayo Clinic and Cleveland Clinic guidance both note these are long-term medications for chronic conditions, not short-term weight-loss tools — and that gastrointestinal side effects are common, particularly during dose escalation.
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and others — have changed obesity medicine in ways that few drug classes have in the last twenty years. The weight-loss results are real. The cardiovascular and metabolic benefits in eligible patients are real. The drugs are also new at this scale of use, and a number of important things are not getting communicated clearly in the brief office visits where prescriptions are written.
This article is not anti-GLP-1. For people who meet medical criteria for these drugs, they can be genuinely useful. The point is to surface what FDA communications, NIH-published research, and Mayo Clinic's drug-information pages flag — but that often gets compressed or skipped in a 15-minute appointment.
What the FDA has actually said
The FDA approved semaglutide for weight loss (Wegovy) in 2021 and tirzepatide for weight loss (Zepbound) in 2023. Both labels include warnings for thyroid C-cell tumors (based on rodent studies — relevance to humans is unclear), acute pancreatitis, gallbladder disease, severe gastrointestinal effects, and acute kidney injury secondary to dehydration from vomiting and diarrhea.
The FDA has also issued repeated safety communications about compounded versions of these drugs — versions made by independent compounding pharmacies during shortages of the brand-name product. Many of the adverse events reported with compounded products appear consistent with adverse events reported for the FDA-approved versions, but quality control on compounded products is uneven. The FDA's guidance is to use FDA-approved products from licensed pharmacies whenever possible.
Side effects most people will experience
Cleveland Clinic's GLP-1 explainer puts gastrointestinal side effects at the top of the list: nausea, diarrhea, constipation, vomiting. Most are dose-dependent and worst during the dose-escalation phase (the first several months). Many patients adapt; some don't.
Less commonly discussed but documented: pancreatitis (often severe enough for hospitalization), gallstones (more common with rapid weight loss generally, GLP-1 included), hair loss (typical with any rapid weight loss), and "Ozempic face" — facial volume loss that's a normal consequence of the underlying fat loss, not a unique drug effect. There's also growing surveillance interest in psychiatric effects: the European Medicines Agency reviewed reports of suicidal ideation and self-harm in 2023; the FDA's review found no causal link, but ongoing monitoring is happening across multiple regulatory bodies.
What happens when you stop the medication
Most published research on long-term use shows that stopping GLP-1 medications leads to substantial weight regain in the absence of meaningful lifestyle change. The STEP-1 trial extension reported that participants regained roughly two-thirds of their lost weight within a year of stopping semaglutide. The biology is consistent: these drugs work in part by reducing appetite signaling, and the appetite signal returns when the drug is discontinued.
What this means practically: GLP-1 use is increasingly framed as a long-term medication for chronic obesity, not a 6-month diet. That changes the cost calculation, the side-effect tolerance calculation, and the conversation about lifestyle changes that need to happen alongside the medication — not after it.
Mayo Clinic's framing — chronic condition, chronic treatment
Mayo Clinic's semaglutide drug information page treats the medication as long-term therapy for adults with chronic weight management needs, alongside lifestyle changes including reduced-calorie diet and increased physical activity. The drug works best as an adjunct, not a replacement.
The patients who do best on these medications, according to Mayo Clinic and Cleveland Clinic guidance, are typically those who use the appetite reduction as a window to build sustainable eating, exercise, and sleep habits — not those who treat the medication as a substitute for those habits. The latter group tends to regain weight when the medication is stopped or coverage is lost; the former group often maintains a meaningful portion of the loss.
To your health,
Ageless CoachTM
Age Strong. Live Long.
Trusted Sources Behind This Article
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reading this article does not create a provider-patient relationship. Always consult your physician or qualified healthcare provider before making changes to your diet, exercise, or health routine. Ageless Coach is not liable for any actions taken based on this information.
Frequently Asked Questions
Want one verified-science article like this every week?
Get Better Health, Weekly